Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 07, 2026 08:00 ET | Source: CRISPR Therapeutics AG

CRISPR Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference

ZUG, Switzerland and BOSTON, April 07, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today announced that members of its senior management team will present at the 25th Annual Needham...
April 07, 2026 08:00 ET | Source: Corbus Pharmaceuticals Holdings, Inc.

Corbus Pharmaceuticals Announces Broad Alignment with FDA on Registration Path for CRB-701 in Second-Line HNSCC and Cervical Cancer

FDA feedback enables Corbus to proceed with proposed registrational study design and endpoints to support potential accelerated approval in second-line HNSCC and cervical cancer Updated CRB-701...
April 07, 2026 08:00 ET | Source: Calidi Biotherapeutics, Inc

Calidi Biotherapeutics Announces Speaker Presentation at ASGCT Conference in Boston on May 14, 2026 Highlighting the RedTail Platform’s Ability to Deliver Genetic Medicines to Distal Sites of Disease with Systemic Therapy

SAN DIEGO, April 07, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic...
April 07, 2026 08:00 ET | Source: Evaxion

Evaxion announces last patient visit in one-year extension of phase 2 trial with personalized cancer vaccine EVX-01

Trial extension completed as planned with three-year clinical efficacy data expected to be presented in the second half of 2026The trial has already yielded encouraging one- and two-year data...
April 07, 2026 07:50 ET | Source: Artelo Biosciences

Artelo Biosciences Regains Compliance with Nasdaq Listing Requirements

SOLANA BEACH, Calif., April 07, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical‑stage pharmaceutical company focused on modulating lipid‑signaling pathways to develop...
April 07, 2026 07:30 ET | Source: Marvel Biosciences Corp.

Marvel Biosciences Secures Financial and Strategic Investment with 5 Horizon Ventures

Marvel announces financial and strategic backing from 5 Horizons Ventures to support its upcoming Phase 1 clinical trial of patented lead asset MB-204
April 07, 2026 07:00 ET | Source: Skye Bioscience, Inc.

Skye Bioscience Presenting at GLP-1-Based Therapeutics Summit

SAN DIEGO, April 07, 2026 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”) a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other...
April 07, 2026 07:00 ET | Source: Climb Bio, Inc.

Climb Bio Announces FDA Fast Track Designation for Budoprutug for the Treatment of Primary Membranous Nephropathy

WELLESLEY HILLS, Mass., April 07, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases,...
April 07, 2026 07:00 ET | Source: AC Immune SA

AC Immune Announces Amendment to Morphomer ® Tau License and Collaboration Agreement with Lilly

AC Immune Announces Amendment to Morphomer ® Tau License and Collaboration Agreement with Lilly Amended agreement reflects growing excitement in the field for targeting intracellular Tau and...
April 07, 2026 07:00 ET | Source: MediWound Ltd.

MediWound to Present New EscharEx® Data at Leading Wound Care Conferences

MediWound to Present New EscharEx® Data at Leading Wound Care Conferences Data highlights mechanism of action, outcomes in VLUs and DFUs, and comparative advantages over SANTYL® Findings support...